[go: up one dir, main page]

NZ757869B2 - Crystalline forms of (s)-afoxolaner - Google Patents

Crystalline forms of (s)-afoxolaner Download PDF

Info

Publication number
NZ757869B2
NZ757869B2 NZ757869A NZ75786918A NZ757869B2 NZ 757869 B2 NZ757869 B2 NZ 757869B2 NZ 757869 A NZ757869 A NZ 757869A NZ 75786918 A NZ75786918 A NZ 75786918A NZ 757869 B2 NZ757869 B2 NZ 757869B2
Authority
NZ
New Zealand
Prior art keywords
crystalline forms
afoxolaner
formula
diffraction pattern
ray powder
Prior art date
Application number
NZ757869A
Other versions
NZ757869A (en
Inventor
Bruno Baillon
De Saint Michel Myriam Gay
De Vries Roelof Johannes Gorter
Stephane Kozlovic
Sylvaine Lafont
Original Assignee
Boehringer lngelheim Vetmedica GMBH
Filing date
Publication date
Application filed by Boehringer lngelheim Vetmedica GMBH filed Critical Boehringer lngelheim Vetmedica GMBH
Priority claimed from PCT/US2018/026328 external-priority patent/WO2018187623A1/en
Publication of NZ757869A publication Critical patent/NZ757869A/en
Publication of NZ757869B2 publication Critical patent/NZ757869B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Abstract

The present invention provides crystalline forms of compound of formula (la) and processes of making the crystalline forms. Also provided are compositions comprising the crystalline forms and crystalline forms for treating or preventing parasitic infections in an animal.

Claims (3)

WHAT IS CLAIMED IS:
1. A crystalline compound of formula (Ia), designated as Form I, wherein said crystalline form is non-solvated and is characterized by having an x-ray powder diffraction pattern comprising three, four, five, six, seven or more peaks selected from the group consisting of: 10.03°, 10.48°, 13.16°, 15.42°, 15.80°, 16.07°, 17.65°, 20.16°, 22.15°, 23.68°, 26.52°, and 28.13° 2 ? ±0.2 as determined on a diffractometer using Cu-K a radiation.
2. The crystalline compound of formula (Ia) according to claim 1, characterized by having an x-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of: 10.03°, 10.48°, 13.16°, 20.16°, and 22.15° 2 ? ±0.2 as determined on a diffractometer using Cu-K a radiation.
3. The crystalline compound of formula (Ia) according to claim 1 or 2, characterized by having an x-ray powder diffraction pattern substantially similar to
NZ757869A 2018-04-05 Crystalline forms of (s)-afoxolaner NZ757869B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762482175P 2017-04-05 2017-04-05
PCT/US2018/026328 WO2018187623A1 (en) 2017-04-05 2018-04-05 Crystalline forms of (s)-afoxolaner

Publications (2)

Publication Number Publication Date
NZ757869A NZ757869A (en) 2024-11-29
NZ757869B2 true NZ757869B2 (en) 2025-03-04

Family

ID=

Similar Documents

Publication Publication Date Title
EP4566612A3 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
WO2018187553A8 (en) Fungicidal oxadiazoles
HRP20120066T1 (en) POTASSIUM SALT OF HIV INTEGRASE INHIBITOR
SI2125850T1 (en) Macrocyclic polymorphs, compositions comprising such polymorphs, methods of manufacture and use thereof
MX2021000348A (en) Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof.
ZA202309546B (en) Agrochemical composition of solid state form of pyroxasulfone
WO2018232005A3 (en) Antimicrobial compounds and nanostructures
WO2015011119A3 (en) Salts of dasatinib in amorphous form
PH12021552513A1 (en) Pyrrole compounds
GEAP202215389A (en) Polymorphs
ZA202105753B (en) Crystalline forms of 1-(1,2-dimethylpropyl)-n-ethyl-5-methyl-n-pyridazin-4-yl-pyrazole-4-carboxamide
WO2019207257A8 (en) Compounds having a tubulin-polymerisation-inhibiting activity and immunomodulatory properties
MX2025014299A (en) Solid form of a quinoline carboxamide compound
WO2019023216A8 (en) Inhibitors of ror gamma
PH12021552953A1 (en) Tricyclic compounds
WO2020016302A8 (en) A xinafoate salt of a jak inhibiting compound
NZ757869B2 (en) Crystalline forms of (s)-afoxolaner
NZ757869A (en) Crystalline forms of (s)-afoxolaner
WO2022074459A3 (en) Autotaxin inhibitor compounds
WO2018102256A8 (en) Pyrrolidinone compounds
CL2025000059A1 (en) Solid form of benzovindiflupyr and fungicidal composition.
NZ738836B2 (en) Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
WO2018139825A3 (en) Imidazopyridazine compound
NZ779311A (en) Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
NZ786434B2 (en) Process for the preparation of isoxazoline compounds